HRP20230359T1 - Imunogeni pripravak - Google Patents
Imunogeni pripravak Download PDFInfo
- Publication number
- HRP20230359T1 HRP20230359T1 HRP20230359TT HRP20230359T HRP20230359T1 HR P20230359 T1 HRP20230359 T1 HR P20230359T1 HR P20230359T T HRP20230359T T HR P20230359TT HR P20230359 T HRP20230359 T HR P20230359T HR P20230359 T1 HRP20230359 T1 HR P20230359T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- fragment
- immunogenic preparation
- preparation according
- oil
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 17
- 239000000203 mixture Substances 0.000 title claims 2
- 239000012634 fragment Substances 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 241000193163 Clostridioides difficile Species 0.000 claims 5
- 239000007764 o/w emulsion Substances 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 4
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 claims 3
- 239000003995 emulsifying agent Substances 0.000 claims 3
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 2
- 101710182223 Toxin B Proteins 0.000 claims 2
- 101710182532 Toxin a Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000003252 repetitive effect Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Imunogeni pripravak koji sadrži:
a) polipeptid koji sadrži izolirani fragment A toksina Clostridium difficile i izolirani fragment B toksina C. difficile pri čemu polipeptid sadrži fragment ponavljajuće domene toksina A i fragment ponavljajuće domene toksina B; i
b) adjuvans koji sadrži emulziju ulja u vodi, pri čemu navedena emulzija ulja u vodi sadrži ulje koje se može metabolizirati, tokol i emulgator;
pri čemu je imunogeni pripravak u volumenu prikladnom za dozu za ljude, koji je volumen 0.5ml ili veći od 0.5 ml, na primjer 0.6, 0.7, 0.8, 0.9 ili 1 ml, ili između 1 ml i 1.5 ml.
2. Imunogeni pripravak prema zahtjevu 1, naznačen time što emulzija ulja u vodi sadrži 1-10, 2-10, 3-9, 4-8, 5-7, ili 5-6 mg metabolizirajućeg ulja, po dozi.
3. Imunogeni pripravak prema bilo kojem od zahtjeva 1 do 2, naznačen time što emulzija ulja u vodi sadrži 0.5-11, 1-11, 2-10, 3-9, 4-8, 5-7, 5-6 mg tokola po dozi.
4. Imunogeni pripravak prema bilo kojem od zahtjeva 1 do 3, naznačen time što emulzija ulja u vodi sadrži 0.1-5, 0.2-5, 0.3-4, 0.4-3 ili 2-3 mg emulgatora po dozi.
5. Imunogeni pripravak prema bilo kojem od zahtjeva 1 do 4 naznačen time što je ulje koje se metabolizira skvalen.
6. Imunogeni pripravak prema jednom od zahtjeva 1 do 5 naznačen time što je tokol alfa-tokoferol.
7. Imunogeni pripravak prema bilo kojem od zahtjeva 1 do 6 naznačen time što je emulgator polioksietilen sorbitan monooleat.
8. Imunogeni pripravak prema bilo kojem prethodnom zahtjevu, naznačen time što polipeptid je polipeptid koji sadrži prvi fragment i drugi fragment, pri čemu
a) prvi fragment je fragment ponavljajuće domene toksina A;
b) drugi fragment je fragment ponavljajuće domene toksina B;
c) prvi fragment ima prvi proksimalni kraj;
d) drugi fragment ima drugi proksimalni kraj; i
pri čemu su prvi fragment i drugi fragment jedan uz drugi.
9. Imunogeni pripravak prema bilo kojem od zahtjeva 1 do 8 naznačen time što polipeptid sadrži:
(i) SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 , SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 ili SEQ ID NO: 34 ili SEQ ID NO: 35; ili
(ii) varijanta koja ima najmanje 90%, 95%, 98%, 99%, ili 100% sličnosti sa SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID BR:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 ili SEQ ID NO:34 ili SEQ ID BR:35; ili
(iii) fragment od najmanje 250, 280, 300, 350, 380, 400, 430, 450, 480, 500, 530, 550, 580 ili 600 aminokiselina SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33 ili SEQ ID NO:34 ili SEQ ID NO:35.
10. Imunogeni pripravak prema bilo kojem od prethodnih zahtjeva nadalje sadrži dodatne antigene.
11. Imunogeni pripravak prema bilo kojem od prethodnih zahtjeva naznačen time što polipeptid izaziva zaštitni imunološki odgovor kod sisavca domaćina protiv sojeva C.difficile.
12. Cjepivo sadrži imunogeni pripravak prema bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljivu pomoćnu tvar.
13. Imunogeni pripravak prema bilo kojem od prethodnih zahtjeva ili cjepivo prema zahtjevu 12 za uporabu u liječenju ili prevenciji bolesti C.difficile.
14. Imunogeni pripravak prema bilo kojem od prethodnih zahtjeva ili cjepivo prema zahtjevu 12 za uporabu u liječenju ili prevenciji bolesti C. difficile, naznačen time što se navedeni imunogeni pripravak ili cjepivo daje ljudskom subjektu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201221875 | 2012-12-05 | ||
| EP19159001.7A EP3513806B1 (en) | 2012-12-05 | 2013-12-03 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230359T1 true HRP20230359T1 (hr) | 2023-06-09 |
Family
ID=49724573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230359TT HRP20230359T1 (hr) | 2012-12-05 | 2013-12-03 | Imunogeni pripravak |
| HRP20190711TT HRP20190711T1 (hr) | 2012-12-05 | 2019-04-16 | Imunogeni pripravak |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190711TT HRP20190711T1 (hr) | 2012-12-05 | 2019-04-16 | Imunogeni pripravak |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9694064B2 (hr) |
| EP (2) | EP2928489B1 (hr) |
| JP (2) | JP6290918B2 (hr) |
| CN (2) | CN112807422A (hr) |
| AR (1) | AR093712A1 (hr) |
| AU (1) | AU2013354186A1 (hr) |
| BR (1) | BR112015012841B1 (hr) |
| CA (1) | CA2893435A1 (hr) |
| CY (1) | CY1121560T1 (hr) |
| DK (2) | DK2928489T3 (hr) |
| ES (2) | ES2939307T3 (hr) |
| FI (1) | FI3513806T3 (hr) |
| HR (2) | HRP20230359T1 (hr) |
| HU (2) | HUE043091T2 (hr) |
| LT (2) | LT2928489T (hr) |
| PL (2) | PL3513806T3 (hr) |
| PT (2) | PT3513806T (hr) |
| SG (1) | SG11201503861UA (hr) |
| SI (2) | SI2928489T1 (hr) |
| TR (1) | TR201905272T4 (hr) |
| WO (1) | WO2014086787A1 (hr) |
| ZA (1) | ZA201503927B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007016403A (es) * | 2005-06-27 | 2008-03-07 | Glaxosmithkline Biolog Sa | Composicion inmunogenica. |
| BR112014004896B1 (pt) | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
| JP5917682B2 (ja) | 2011-04-22 | 2016-05-18 | ワイス・エルエルシー | 変異体クロストリジウム・ディフィシル毒素に関する組成物およびその方法 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| SI2928489T1 (sl) * | 2012-12-05 | 2019-05-31 | Glaxosmithkline Biologicals S.A. | Imunogeni sestavek |
| PL3160500T3 (pl) * | 2014-06-25 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Immunogenna kompozycja clostridium difficile |
| HUE038212T2 (hu) * | 2014-07-25 | 2018-10-29 | Biosynth Srl | Többszörös beépített epitópokat kifejezõ molekuláris konstrukt bázikus egységeket tartalmazó glikokonjugátum vakcinák enteropatogén baktériumok által okozott fertõzések elleni szélesspektrumú vakcina elõállításához |
| ES2870506T3 (es) | 2015-02-19 | 2021-10-27 | Immune Biosolutions Inc | Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos |
| CA3014498A1 (en) | 2016-03-21 | 2017-09-28 | Children's Medical Center Corporation | Compositions and methods for inhibiting wnt signaling |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3595709A4 (en) | 2017-03-15 | 2020-12-23 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE |
| CN107397956A (zh) * | 2017-08-08 | 2017-11-28 | 南开大学 | 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用 |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| EP0362278A4 (en) | 1987-06-05 | 1990-05-14 | Us Health | FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER. |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DK0382271T3 (da) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoler som adjuvanser i vacciner |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
| ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| ATE366312T1 (de) | 1994-10-24 | 2007-07-15 | Ophidian Pharm Inc | Impfstoff und antitoxine zur behandlung und vorbeugung von c. difficile krankheiten |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP1024826B1 (en) | 1997-10-20 | 2005-03-16 | Acambis, Inc. | Passive immunization against clostridium difficile disease |
| JP2002542169A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| GB0525321D0 (en) * | 2005-12-13 | 2006-01-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| KR101151202B1 (ko) * | 2006-10-12 | 2012-06-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 수중유 에멀젼 애주번트를 포함하는 백신 |
| GB0711858D0 (en) | 2007-06-19 | 2007-07-25 | Glaxosmithkline Biolog Sa | Vaccine |
| HUE037932T2 (hu) | 2007-09-14 | 2018-09-28 | Sanofi Pasteur Biologics Llc | Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók |
| EP2612680B1 (en) * | 2008-04-16 | 2018-05-23 | GlaxoSmithKline Biologicals SA | Vaccine |
| CA2733425A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| BR112014004896B1 (pt) * | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
| ES2615737T3 (es) | 2011-05-27 | 2017-06-08 | Glaxosmithkline Biologicals S.A. | Composición inmunogénica |
| SI2928489T1 (sl) * | 2012-12-05 | 2019-05-31 | Glaxosmithkline Biologicals S.A. | Imunogeni sestavek |
-
2013
- 2013-12-03 SI SI201331393T patent/SI2928489T1/sl unknown
- 2013-12-03 WO PCT/EP2013/075405 patent/WO2014086787A1/en active Application Filing
- 2013-12-03 SI SI201332035T patent/SI3513806T1/sl unknown
- 2013-12-03 CN CN202011473000.5A patent/CN112807422A/zh active Pending
- 2013-12-03 AR ARP130104466A patent/AR093712A1/es unknown
- 2013-12-03 HR HRP20230359TT patent/HRP20230359T1/hr unknown
- 2013-12-03 LT LTEP13801540.9T patent/LT2928489T/lt unknown
- 2013-12-03 CA CA2893435A patent/CA2893435A1/en active Pending
- 2013-12-03 AU AU2013354186A patent/AU2013354186A1/en not_active Abandoned
- 2013-12-03 HU HUE13801540A patent/HUE043091T2/hu unknown
- 2013-12-03 PT PT191590017T patent/PT3513806T/pt unknown
- 2013-12-03 ES ES19159001T patent/ES2939307T3/es active Active
- 2013-12-03 PT PT13801540T patent/PT2928489T/pt unknown
- 2013-12-03 DK DK13801540.9T patent/DK2928489T3/en active
- 2013-12-03 BR BR112015012841-6A patent/BR112015012841B1/pt active IP Right Grant
- 2013-12-03 TR TR2019/05272T patent/TR201905272T4/tr unknown
- 2013-12-03 PL PL19159001.7T patent/PL3513806T3/pl unknown
- 2013-12-03 LT LTEP19159001.7T patent/LT3513806T/lt unknown
- 2013-12-03 US US14/649,940 patent/US9694064B2/en active Active
- 2013-12-03 EP EP13801540.9A patent/EP2928489B1/en active Active
- 2013-12-03 CN CN201380063596.3A patent/CN104884081A/zh active Pending
- 2013-12-03 FI FIEP19159001.7T patent/FI3513806T3/fi active
- 2013-12-03 EP EP19159001.7A patent/EP3513806B1/en active Active
- 2013-12-03 JP JP2015545783A patent/JP6290918B2/ja active Active
- 2013-12-03 SG SG11201503861UA patent/SG11201503861UA/en unknown
- 2013-12-03 ES ES13801540T patent/ES2721930T3/es active Active
- 2013-12-03 DK DK19159001.7T patent/DK3513806T3/da active
- 2013-12-03 HU HUE19159001A patent/HUE061273T2/hu unknown
- 2013-12-03 PL PL13801540T patent/PL2928489T3/pl unknown
-
2015
- 2015-06-01 ZA ZA2015/03927A patent/ZA201503927B/en unknown
-
2017
- 2017-05-26 US US15/606,439 patent/US10130694B2/en active Active
-
2018
- 2018-02-08 JP JP2018020900A patent/JP6626521B2/ja active Active
-
2019
- 2019-04-16 HR HRP20190711TT patent/HRP20190711T1/hr unknown
- 2019-04-19 CY CY20191100436T patent/CY1121560T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230359T1 (hr) | Imunogeni pripravak | |
| Chen et al. | Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement | |
| Wang et al. | The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb | |
| Gasparini et al. | Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects | |
| HRP20220717T1 (hr) | Modificirani pripravci mrna | |
| HRP20191291T1 (hr) | Imunogeni pripravak | |
| Verhoeven et al. | Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model | |
| TW200722101A (en) | Novel composition | |
| TWI630915B (zh) | 無細胞百日咳疫苗 | |
| BR112013005427A2 (pt) | composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica. | |
| EP3125930B1 (en) | Novel methods for inducing an immune response | |
| BRPI0918806A2 (pt) | composição compreendendo quitosana para administração ocular de vaninas em aves | |
| MX341775B (es) | Vectores para vacunas y metodos para potenciar respuestas inmunes. | |
| Xu et al. | Intake of Korean red ginseng extract and saponin enhances the protection conferred by vaccination with inactivated influenza A virus | |
| BR112023000730A2 (pt) | Método para induzir e/ou ativar uma resposta imune, forma de dosagem, kit, vetor, célula hospedeira, partículas do vetor lentiviral pseudotipada e composição imunogênica | |
| Triglav et al. | Vaccination indications and limits in the elderly | |
| Lei et al. | Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice | |
| Hu et al. | A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination | |
| JP2017511324A5 (hr) | ||
| Habibi et al. | Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model | |
| Alesci et al. | Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines | |
| Ikematsu et al. | Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan | |
| BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
| Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
| Jia et al. | Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses |